{"id":"W4283706254","doi":"10.1136/annrheumdis-2022-eular.1691","title":"POS1037 EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Sanofi Genzyme; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; Sun Pharma; Dermira; Genentech; Coherus Biosciences; College of Medicine, Drexel University; Janssen Scientific Affairs; Valeant Pharmaceuticals International; Leids Universitair Medisch Centrum; Universiteit Leiden; Drexel University; Regeneron Pharmaceuticals; Baxalta; AbbVie; Celgene; Amgen; Pfizer; EMD Serono; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; BASDAI; Placebo; Internal medicine; Axial spondyloarthritis; Sacroiliitis; Ankylosing spondylitis; Clinical endpoint; Randomized controlled trial; Surgery; Gastroenterology; Arthritis; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00123761,0.001419083,0.003485129,0.0004089117,0.0004545351,0.0009168416,0.0007509642,0.001638738,0.004257732],"category_scores_gemma":[0.0009215284,0.0006372179,0.002152503,0.0004361483,0.001052763,0.001304168,0.0002735946,0.003209589,0.001113866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003970944,"about_ca_system_score_gemma":0.0008258719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006519942,"about_ca_topic_score_gemma":0.001533265,"domain_scores_codex":[0.9995046,0.0002173038,0.00003613067,0.00008573888,0.00004171126,0.0001145246],"domain_scores_gemma":[0.9993595,0.0001719404,0.0001209276,0.00005008025,0.00004078047,0.000256778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9423743,0.008434664,0.0009050554,0.0006575617,0.001248192,0.00008538155,0.00005245252,0.0004135984,0.00924713,0.00007072023,0.0008209455,0.03568997],"study_design_scores_gemma":[0.7558923,0.2317853,0.008889988,0.00005259604,0.0007951757,0.00008128215,0.00004744611,0.0005218877,0.00118941,0.0001158706,0.0005959867,0.00003264448],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890411,0.006962221,0.0004129651,0.0004298177,0.000318075,0.0005284761,0.0006891133,0.0001635014,0.001454737],"genre_scores_gemma":[0.9924713,0.002803008,0.0005739818,0.0007794257,0.0002818296,0.0005621201,0.0009288069,0.00002992449,0.001569554],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004257732,"threshold_uncertainty_score":0.01424354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01838601258385054,"score_gpt":0.3039299250623363,"score_spread":0.2855439124784858,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}